NO871199L - Fremgangsmaate for fremstilling av farmasoeytiske preparater med langvarige frigjoeringsegenskaper. - Google Patents

Fremgangsmaate for fremstilling av farmasoeytiske preparater med langvarige frigjoeringsegenskaper.

Info

Publication number
NO871199L
NO871199L NO87871199A NO871199A NO871199L NO 871199 L NO871199 L NO 871199L NO 87871199 A NO87871199 A NO 87871199A NO 871199 A NO871199 A NO 871199A NO 871199 L NO871199 L NO 871199L
Authority
NO
Norway
Prior art keywords
preparation
procedure
long
pharmaceutical preparations
release properties
Prior art date
Application number
NO87871199A
Other languages
English (en)
Other versions
NO174795C (no
NO174795B (no
NO871199D0 (no
Inventor
Karl-Erik Lennart Falk
Sven Morgan Hugosson
Adam Rosinski
John Albert Sjogren
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20364135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO871199(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of NO871199D0 publication Critical patent/NO871199D0/no
Publication of NO871199L publication Critical patent/NO871199L/no
Publication of NO174795B publication Critical patent/NO174795B/no
Publication of NO174795C publication Critical patent/NO174795C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO871199A 1986-04-11 1987-03-23 Fremgangsmåte for fremstilling av faste farmasöytiske preparater som inneholder estere og/eller etere av polyetylenglykoler som opplöseliggjörende middel NO174795B (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8601624A SE8601624D0 (sv) 1986-04-11 1986-04-11 New pharmaceutical preparations

Publications (4)

Publication Number Publication Date
NO871199D0 NO871199D0 (no) 1987-03-23
NO871199L true NO871199L (no) 1987-10-12
NO174795B NO174795B (no) 1994-04-05
NO174795C NO174795C (no) 1994-07-13

Family

ID=20364135

Family Applications (1)

Application Number Title Priority Date Filing Date
NO871199A NO174795B (no) 1986-04-11 1987-03-23 Fremgangsmåte for fremstilling av faste farmasöytiske preparater som inneholder estere og/eller etere av polyetylenglykoler som opplöseliggjörende middel

Country Status (34)

Country Link
US (1) US4803081A (no)
EP (1) EP0249587B1 (no)
JP (1) JPH0778016B2 (no)
KR (2) KR870009720A (no)
CN (1) CN1025150C (no)
AT (1) ATE76288T1 (no)
AU (1) AU602677B2 (no)
CA (1) CA1304294C (no)
CS (1) CS270560B2 (no)
CY (1) CY1826A (no)
DD (1) DD263231A5 (no)
DE (1) DE3779183D1 (no)
DK (1) DK173033B1 (no)
DZ (1) DZ1067A1 (no)
EG (1) EG18265A (no)
ES (1) ES2031929T3 (no)
FI (1) FI91826C (no)
GR (1) GR3005286T3 (no)
HK (1) HK26795A (no)
HU (1) HU204699B (no)
IE (1) IE59419B1 (no)
IS (1) IS1553B (no)
MY (1) MY101553A (no)
NO (1) NO174795B (no)
NZ (1) NZ219633A (no)
PH (1) PH22494A (no)
PL (1) PL265078A1 (no)
PT (1) PT84663B (no)
SE (1) SE8601624D0 (no)
SG (1) SG4295G (no)
SU (1) SU1743332A3 (no)
UA (1) UA12336A (no)
YU (1) YU47258B (no)
ZA (1) ZA871911B (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
AU3243393A (en) * 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
DE69332081T2 (de) 1992-09-18 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelzubereitung mit verzögerter freisetzung
JP3598049B2 (ja) * 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
DK0589843T3 (da) 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5800834A (en) * 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
EP0859603B1 (en) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
KR20050084502A (ko) 1997-01-30 2005-08-26 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
AR017512A1 (es) 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
KR100463496B1 (ko) * 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 고가용성 약물용 서방성 메트리스 시스템
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
NZ521853A (en) * 2000-04-11 2003-11-28 Sankyo Co Stabilized pharmaceutical compositions containing a calcium blocker
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
WO2002056883A1 (en) * 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
US9820982B2 (en) * 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2447984A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60323474D1 (de) 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
ES2286486T3 (es) * 2002-12-17 2007-12-01 ABBOTT GMBH & CO. KG Formulacion que comprende acido fenofibrico, una sal o un derivado fisiologicamente aceptables del mismo.
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
PL1915137T3 (pl) * 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US9419566B2 (en) 2011-04-20 2016-08-16 Freescale Semiconductor, Inc. Amplifiers and related integrated circuits
CN104997750B (zh) * 2015-07-30 2018-03-20 杭州康恩贝制药有限公司 一种非洛地平缓释片及其制备方法
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
CN109200026B (zh) * 2017-07-03 2021-01-05 北京四环科宝制药有限公司 一种非洛地平缓释片及其制备方法
US11417416B2 (en) 2018-06-14 2022-08-16 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
JPS5495721A (en) * 1978-01-11 1979-07-28 Nippon Kayaku Co Ltd Nifedipine preparation
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3400106A1 (de) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
WO1985004100A1 (en) * 1984-03-21 1985-09-26 American Home Products Corporation Sustained release pharmaceutical capsules
JPS618A (ja) * 1984-06-09 1986-01-06 Sawai Seiyaku Kk ニフエジピン含有製剤
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Also Published As

Publication number Publication date
CS270560B2 (en) 1990-07-12
DK154987A (da) 1987-10-12
FI91826C (fi) 1994-08-25
NO174795C (no) 1994-07-13
KR870009720A (ko) 1987-11-30
IS3214A7 (is) 1987-10-12
PT84663B (pt) 1989-11-30
DZ1067A1 (fr) 2004-09-13
CA1304294C (en) 1992-06-30
NO174795B (no) 1994-04-05
FI91826B (fi) 1994-05-13
CN1025150C (zh) 1994-06-29
JPH0778016B2 (ja) 1995-08-23
DD263231A5 (de) 1988-12-28
JPS62242613A (ja) 1987-10-23
YU40787A (sh) 1992-09-07
IE870925L (en) 1987-10-11
HK26795A (en) 1995-03-10
IS1553B (is) 1994-08-10
HUT43786A (en) 1987-12-28
AU602677B2 (en) 1990-10-25
MY101553A (en) 1991-12-17
GR3005286T3 (no) 1993-05-24
CY1826A (en) 1995-12-01
PH22494A (en) 1988-09-12
YU47258B (sh) 1995-01-31
SE8601624D0 (sv) 1986-04-11
NO871199D0 (no) 1987-03-23
DK154987D0 (da) 1987-03-26
IE59419B1 (en) 1994-02-23
EG18265A (en) 1992-12-30
SU1743332A3 (ru) 1992-06-23
CS258787A2 (en) 1989-11-14
ATE76288T1 (de) 1992-06-15
EP0249587B1 (en) 1992-05-20
HU204699B (en) 1992-02-28
CN87102758A (zh) 1987-10-21
DE3779183D1 (de) 1992-06-25
ES2031929T3 (es) 1993-01-01
EP0249587A1 (en) 1987-12-16
KR950002147B1 (ko) 1995-03-14
PT84663A (en) 1987-05-01
FI871585L (fi) 1987-10-12
US4803081A (en) 1989-02-07
ZA871911B (en) 1987-12-30
PL265078A1 (en) 1988-07-21
DK173033B1 (da) 1999-11-29
UA12336A (uk) 1996-12-25
NZ219633A (en) 1989-11-28
KR890001521A (ko) 1989-03-27
FI871585A0 (fi) 1987-04-10
SG4295G (en) 1995-06-16
AU7004387A (en) 1987-10-15

Similar Documents

Publication Publication Date Title
NO871199D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater med langvarige frigjoeringsegenskaper.
SE8402549L (sv) Substituerade moranolinderivat
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
ES2130111T3 (es) Derivados de ciclohexano, preparaciones que los contienen y su utilizacion.
ATE16191T1 (de) Stabile salze von s-adenosinylmethionin, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen welche als aktive substanz diese derivate enthalten.
DE3382637D1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
ATE67406T1 (de) Nicorandil enthaltende zubereitung zum einspritzen.
FR2397191A1 (fr) Preparation stable de chloramphenicol pour injections
DK486879A (da) Fremgangsmaade til fremstilling af aminopropanolderivater af 6-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepin-2-on eller syreadditionssalte deraf
IT1143921B (it) Derivati di acidi alcanoici dotati di proprieta' terapeutiche e procedimento per la loro preparazione
FR2446831A1 (fr) Derive oxyimino-e-homo-eburnane, procede pour le preparer et son utilisation dans une composition pharmaceutique pour la preparation de derives ester de l'acide apovincaminique
GR890100737A (el) Μέ?οδος παρασκευής μιας φαρμακευτικής συν?έσεως δι'οφ?αλμική χρήσιν η οποία περιλαμβάνει ένα υδατοδιαλυτό άλας δια προσ?ήκης οξέος ιμποπαμίνης.
SE7902817L (sv) Substituerade /4h/ 1,3-bensodioxin-2-karboxylsyraderivat, framstellning och anvendning derav sasom lekemedel samt farmaceutiska kompositioner innehallande dessa
DE3778858D1 (de) 17-benzylspartein-derivate enthaltende positiv inotrop wirksame pharmazeutische zubereitungen.
ATE78402T1 (de) Waesserige loesungen von doxorubicin.